Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Jul 16, 2020

SELL
$72.34 - $84.0 $193,075 - $224,196
-2,669 Closed
0 $0
Q1 2020

Apr 28, 2020

BUY
$62.63 - $80.22 $167,159 - $214,107
2,669 New
2,669 $200,000
Q4 2019

Jan 15, 2020

SELL
$61.62 - $67.78 $190,898 - $209,982
-3,098 Closed
0 $0
Q3 2019

Oct 29, 2019

SELL
$62.51 - $69.0 $51,945 - $57,339
-831 Reduced 21.15%
3,098 $196,000
Q2 2019

Jul 29, 2019

SELL
$61.87 - $69.38 $1,608 - $1,803
-26 Reduced 0.66%
3,929 $265,000
Q1 2019

Apr 29, 2019

BUY
$62.53 - $70.05 $15,632 - $17,512
250 Added 6.75%
3,955 $257,000
Q4 2018

Jan 17, 2019

BUY
$60.54 - $79.0 $224,300 - $292,695
3,705 New
3,705 $232,000
Q3 2018

Nov 06, 2018

SELL
$71.28 - $78.92 $204,644 - $226,579
-2,871 Closed
0 $0
Q2 2018

Aug 07, 2018

SELL
$64.88 - $75.68 $13,949 - $16,271
-215 Reduced 6.97%
2,871 $203,000
Q1 2018

May 04, 2018

BUY
$72.84 - $88.8 $224,784 - $274,036
3,086 New
3,086 $233,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Kcs Wealth Advisory Portfolio

Follow Kcs Wealth Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kcs Wealth Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Kcs Wealth Advisory with notifications on news.